Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer (PLASTIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03208621|
Recruitment Status : Recruiting
First Posted : July 5, 2017
Last Update Posted : November 17, 2017
Objective: To evaluate the impact and cost-effectiveness of FDG-PET/CT (PET) and diagnostic laparoscopy (DLS) in addition to initial staging by CT and gastroscopy in patients with advanced gastric cancer.
Hypothesis: The study hypothesizes that performing DLS and PET for advanced gastric adenocarcinomas results in a reduction in the number of futile gastrectomies performed and a favorable cost-effectiveness. According to the literature, in 27% of patients a futile gastrectomy can be prevented, and the annual cost-reduction is an estimated €916.438.
Study design: The study design is a prospective observational study. Study population: The study population consists of patients with a surgically resectable, advanced gastric adenocarcinoma (cT3-4a,N0-3,M0), that are scheduled for treatment with curative intent after initial staging with gastroscopy and CT.
Usual care / comparison: Both PET and DLS were recently included in the new Dutch guidelines for the treatment of gastric cancer, as staging modalities for advanced (T3-4) tumors after initial staging. The costs of the study population will be compared to retrospective data of patients who underwent curative surgery (gastrectomy) after initial staging with CT alone.
Outcome measures: The primary outcome of this study will be the proportion of patients in whom the PET or DLS lead to a change in treatment strategy. The accuracy of each modality will be analyzed separately. Secondary outcome parameters will be diagnostic performance, morbidity and mortality, quality of life, cost-reduction and cost-effectiveness.
Sample size: Based on the expectation that 22% of patients will have a change in treatment strategy, at least 239 patients will be needed for this study to demonstrate that the diagnostic modalities in the new guideline are break-even. Approximately 543 patients will be eligible for the study in 36 months.
Cost-effectiveness analysis: A state-of-the-art cost-effectiveness analysis and budget impact analysis will be performed on the additive value of PET and DLS by both prospective and retrospective data collection
|Condition or disease|
|Gastric Cancer Staging FDG-PET/CT Diagnostic Laparoscopy|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||543 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer: a Multicenter Prospective Study|
|Actual Study Start Date :||August 1, 2017|
|Estimated Primary Completion Date :||August 1, 2020|
|Estimated Study Completion Date :||August 1, 2025|
The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
- Change in treatment strategy [ Time Frame: 6 months after performing staging ]The primary outcome of this study will be the proportion of patients in whom the PET or DLS lead to a change in treatment strategy.
- Diagnostic performance [ Time Frame: 6 months after performing staging ]Sensitivity, specificity, positive predictive value and negative predictive value of FDG/PET-CT and Diagnostic Laparoscopy
- Morbidity [ Time Frame: 3 months after performing staging ]Complications of staging modalities
- Quality of life [ Time Frame: Up to 5 years postoperative ]Quality of life with EORTC questionnaires
- Cost-reduction [ Time Frame: 6 months after performing staging ]Annual reduction in costs in the Netherlands of FDG-PET/CT and diagnostic laparoscopy, measured by reviewing hospital financial files and comparing with the previous situation without the staging
- Cost-effectiveness [ Time Frame: 6 months after performing staging ]Cost-effectiveness of FDG-PET/CT and diagnostic laparoscopy, measured by reviewing hospital financial files and comparing with the previous situation without the staging modalities
- Mortality [ Time Frame: 3 months after performing staging ]90-day mortality of the staging modalities
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03208621
|University Medical Center Utrecht||Recruiting|
|Utrecht, Netherlands, 3584 CX|
|Contact: Jelle Ruurda, MD PhD +31 (0)88-755 8074 email@example.com|
|Contact: Hylke Brenkman, MD +31 (0)88-755 8074 firstname.lastname@example.org|
|Principal Investigator: Jelle P Ruurda, MD PhD|
|Sub-Investigator: Hylke JF Brenkman, MD|
|Sub-Investigator: Richard van Hillegersberg, MD PhD|